The revised OMP Regulation will set the tone for rare disease R&D in Europe for the next 20 – 30 years.
In our latest podcast, we deep-dive into the implications of specific European Commission proposals, and discuss how rare disease developers view the introduction of concepts such as high unmet medical need (HUMN) as the basis for a modulated incentive framework.
Diego Ardigò of Chiesi Global Rare Diseases and EUCOPE’s Alexander Natz lead the discussion moderated by EUCOPE’s Victor Maertens and propose alternative models such as the framework developed by the OD Expert Group.
Full episode available here: https://www.eucope.org/sounds-of-science-podcast-16-on-omp-revisions-effects-on-rare-disease-companies/